Gilteritinib is primarily used in the treatment of acute myeloid leukemia (AML), particularly for patients with FLT3 mutations. It functions as a FLT3 inhibitor, targeting and blocking the activity of the FLT3 receptor tyrosine kinase, which is often mutated in AML and contributes to the proliferation of leukemia cells. This targeted therapy helps to reduce the growth of cancer cells and improve patient outcomes. It is especially beneficial for relapsed or refractory AML cases where other treatments have failed. Gilteritinib is administered orally, making it a convenient option for patients. Its use has shown significant improvements in overall survival and remission rates, offering a promising therapeutic option for this challenging condition.